SCHEMBL7735790

SCHEMBL7735790

CCCCn1ccc(-c2cc(OC)ccc2OCCN2CCOCC2)c(N)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
TNF P01375 2/20 0.43
HTR2B P41595 3/20 0.43
MAPK1 P28482 2/20 0.43
HTR2A P28223 2/20 0.43
KCNH2 Q12809 2/20 0.43
CYP1A2 P05177 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
SCN1A P35498 1/20 0.43
SCN2A Q99250 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
SCN3A Q9NY46 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7725848 0.91 ACHE (0.44) KDM4EHTR2BHTR2AHRH3LMNA
SCHEMBL7736225 0.87 HRH3 (0.44) ALDH1A1KDM4EHRH3PTPN1ACHE
SCHEMBL7726191 0.79 SOAT1 (0.43) TNFHTR2AKCNH2HTR2C
SCHEMBL7736090 0.79 TLR4 (0.43) ALDH1A1TLR7
SCHEMBL7734415 0.78 MEN1 (0.46) ALDH1A1KDM4EUSP2LMNATSHR
SCHEMBL7726225 0.75 NPC1 (0.40) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL13791083 0.71 SYK (0.59) ALDH1A1KDM4EHTR2BMAPK1HTR2A
SCHEMBL7735831 0.71 HTR2A (0.46) KDM4EHTR2ALMNAHTR2CSMN1; SMN2
SCHEMBL14930203 0.70 ALDH1A1 (0.68) ALDH1A1KDM4EGAAHTR2BMAPK1
SCHEMBL2428620 0.70 ALDH1A1 (0.51) ALDH1A1KDM4EHTR2BCYP1A2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK ALDH1A1 716/4885KDM4E 139/4885GLA 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.